Ipilimumab-mediated CTLA-4 inhibition shows responses in about one-third of patients experiencing relapsed AML or other hematologic malignancies following allo-HCT, while maintaining a manageable safety profile (25, 87). The gene discussed is CTLA4; the disease is hematologic disorder.